estudio soul semaglutide El Dr. Gonzalo Pérez analiza el SOUL, presentado en el Congreso ACC 2025 y publicado en NEJM. ¿Qué revela el estudio? 🔹 El oral reduce eventos cardiovasculares en personas con estudio soul semaglutide ADA 2025:

GLP-1s can be used to lower the noisereducing intense cravings and stabilizing blood sugar to create a crucial window of opportunity

Her skin finally looked as rested as she felt

Blood work to assess thyroid function, insulin levels, hormone balance, and vitamin deficiencies can reveal underlying issues

Patient-safe next step Compare the claim with the BPC-157 guide, safety notes, access rules, and a licensed-provider review

Clinicians should maintain awareness of these variables when prescribing GLP-1 receptor agonists, particularly in patients with pre-existing osteoporosis or multiple fracture risk factors

Some people may see substantial benefits even at lower doses